Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells

Abstract

Plasmacytoid dendritic cells (pDCs) constitute a rare type of immune cell with multifaceted functions, but their potential use as a cell-based immunotherapy is challenged by the scarce cell numbers that can be extracted from blood. Here, we systematically investigate culture parameters for generating pDCs from hematopoietic stem and progenitor cells (HSPCs). Using optimized conditions combined with implementation of HSPC pre-expansion, we generate an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord blood-derived HSPCs. Furthermore, we demonstrate that such protocol allows HSPC-pDC generation from whole blood HSPCs, and these cells display a pDC phenotype and function. Using GMP compliant medium, we observe a remarkable loss of TLR7/9 responses, which is rescued by ascorbic acid supplementation. Ascorbic acid induces transcriptional signatures associated with pDC-specific innate immune pathways suggesting an undescribed role of ascorbic acid for pDC functionality. This constitutes the first protocol for generating pDCs from whole blood, and lay the foundation for investigating HSPC-pDCs for cell-based immunotherapy.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Sequencing data have been deposited in Dryad (doi:10.5061/dryad.69p8cz92z).

The following data sets were generated

Article and author information

Author details

  1. Anders Laustsen

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    Anders Laustsen, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Part-time employees of UNIKUM Therapeutics ApS..
  2. Renée M van der Sluis

    Department of Biomedicine, Aarhus University, Aarhus C., Denmark
    Competing interests
    No competing interests declared.
  3. Albert Gris-Oliver

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1802-9541
  4. Sabina Sánchez Hernández

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  5. Ena Cemalovic

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  6. Hai Q Tang

    Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus N., Denmark
    Competing interests
    No competing interests declared.
  7. Lars Henning Pedersen

    Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus N., Denmark
    Competing interests
    No competing interests declared.
  8. Niels Uldbjerg

    Department of Clinical Medicine, niels uldbjerg, Aarhus V, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6449-6426
  9. Martin R Jakobsen

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    For correspondence
    mrj@biomed.au.dk
    Competing interests
    Martin R Jakobsen, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Serves on the board of directors of UNIKUM Therapeutics ApS..
  10. Rasmus O Bak

    Department of Biomedicine, Aarhus University, Aarhus C., Denmark
    For correspondence
    bak@biomed.au.dk
    Competing interests
    Rasmus O Bak, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Part-time employees of UNIKUM Therapeutics ApS. Holds equity in Graphite Bio..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7383-0297

Funding

Lundbeckfonden (R238-2016-3349)

  • Rasmus O Bak

Aarhus Institute of Advanced Studies, Aarhus Universitet

  • Renée M van der Sluis
  • Rasmus O Bak

European Union (609033)

  • Rasmus O Bak

Lundbeckfonden (R238-2016-2708)

  • Martin R Jakobsen

Independent Research Fund Denmark (8020-00201B)

  • Martin R Jakobsen

Novo Nordisk Fonden (NNF18OC0053146)

  • Martin R Jakobsen

European Union (754513)

  • Renée M van der Sluis

Carlsbergfondet (CF17-0129)

  • Rasmus O Bak

Carlsbergfondet (CF20-0424)

  • Rasmus O Bak

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Carlos Isales, Medical College of Georgia at Augusta University, United States

Ethics

Human subjects: De-identified umbilical cord blood (UCB) samples were obtained following scheduled caesarean section deliveries of healthy infants at Department of Gynecology and Obstetrics, Skejby University Hospital. Consent was obtained from the mothers, but studies on anonymized samples, such as those used in the present study, are exempt from ethical permissions in Denmark (Kommiteeloven {section sign} {section sign}14. 3).Buffy coat samples were obtained from normal healthy donors from Aarhus University Hospital Blood Bank. These were de-identified samples and studies on anonymized samples are exempt from ethical permissions in Denmark (Kommiteeloven {section sign} {section sign}14. 3).

Version history

  1. Received: December 7, 2020
  2. Accepted: September 1, 2021
  3. Accepted Manuscript published: September 2, 2021 (version 1)
  4. Version of Record published: September 16, 2021 (version 2)

Copyright

© 2021, Laustsen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,617
    views
  • 234
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anders Laustsen
  2. Renée M van der Sluis
  3. Albert Gris-Oliver
  4. Sabina Sánchez Hernández
  5. Ena Cemalovic
  6. Hai Q Tang
  7. Lars Henning Pedersen
  8. Niels Uldbjerg
  9. Martin R Jakobsen
  10. Rasmus O Bak
(2021)
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
eLife 10:e65528.
https://doi.org/10.7554/eLife.65528

Share this article

https://doi.org/10.7554/eLife.65528

Further reading

    1. Immunology and Inflammation
    Xiuyuan Lu, Hiroki Hayashi ... Sho Yamasaki
    Research Article

    SARS-CoV-2 vaccines have been used worldwide to combat COVID-19 pandemic. To elucidate the factors that determine the longevity of spike (S)-specific antibodies, we traced the characteristics of S-specific T cell clonotypes together with their epitopes and anti-S antibody titers before and after BNT162b2 vaccination over time. T cell receptor (TCR) αβ sequences and mRNA expression of the S-responded T cells were investigated using single-cell TCR- and RNA-sequencing. Highly expanded 199 TCR clonotypes upon stimulation with S peptide pools were reconstituted into a reporter T cell line for the determination of epitopes and restricting HLAs. Among them, we could determine 78 S epitopes, most of which were conserved in variants of concern (VOCs). After the 2nd vaccination, T cell clonotypes highly responsive to recall S stimulation were polarized to follicular helper T (Tfh)-like cells in donors exhibiting sustained anti-S antibody titers (designated as ‘sustainers’), but not in ‘decliners’. Even before vaccination, S-reactive CD4+ T cell clonotypes did exist, most of which cross-reacted with environmental or symbiotic microbes. However, these clonotypes contracted after vaccination. Conversely, S-reactive clonotypes dominated after vaccination were undetectable in pre-vaccinated T cell pool, suggesting that highly responding S-reactive T cells were established by vaccination from rare clonotypes. These results suggest that de novo acquisition of memory Tfh-like cells upon vaccination may contribute to the longevity of anti-S antibody titers.

    1. Chromosomes and Gene Expression
    2. Immunology and Inflammation
    Rajan M Thomas, Matthew C Pahl ... Andrew D Wells
    Research Article

    Ikaros is a transcriptional factor required for conventional T cell development, differentiation, and anergy. While the related factors Helios and Eos have defined roles in regulatory T cells (Treg), a role for Ikaros has not been established. To determine the function of Ikaros in the Treg lineage, we generated mice with Treg-specific deletion of the Ikaros gene (Ikzf1). We find that Ikaros cooperates with Foxp3 to establish a major portion of the Treg epigenome and transcriptome. Ikaros-deficient Treg exhibit Th1-like gene expression with abnormal production of IL-2, IFNg, TNFa, and factors involved in Wnt and Notch signaling. While Ikzf1-Treg-cko mice do not develop spontaneous autoimmunity, Ikaros-deficient Treg are unable to control conventional T cell-mediated immune pathology in response to TCR and inflammatory stimuli in models of IBD and organ transplantation. These studies establish Ikaros as a core factor required in Treg for tolerance and the control of inflammatory immune responses.